RecruitingNCT07356050
Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Sponsor
Children's Hospital Medical Center, Cincinnati
Enrollment
130 participants
Start Date
Mar 13, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Eligibility
Min Age: 6 MonthsMax Age: 6 Years
Inclusion Criteria4
- Participants with confirmed Sickle Cell Disease.
- Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
- Willing and able to provide informed consent
- Ability to comply with study related evaluations and follow-up visits.
Exclusion Criteria1
- \. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07356050
Related Trials
Sickle Cell, Pain and Mediterranean Diet
NCT068864771 location
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
NCT0697586553 locations
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
NCT039378171 location
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT0692497032 locations
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT0643908230 locations